SAVA – Cassava Sciences, Inc.
SAVA — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
16.7
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
-1.4
EPS This/Next Y
0.71
Price
2.37
Target Price
8
Analyst Recom
1
Performance Q
-25.39
Upside
N/A
Beta
-0.82
Ticker: SAVA
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | SAVA | 2.12 | 0.25 | 0.73 | 35831 |
| 2026-03-10 | SAVA | 2.38 | 0.25 | 0.02 | 36187 |
| 2026-03-11 | SAVA | 2.38 | 0.25 | 0.02 | 36187 |
| 2026-03-12 | SAVA | 2.38 | 0.25 | 0.02 | 36187 |
| 2026-03-13 | SAVA | 2.38 | 0.25 | 0.02 | 36187 |
| 2026-03-17 | SAVA | 2.38 | 0.25 | 0.02 | 36187 |
| 2026-03-18 | SAVA | 2.38 | N/A | N/A | 0 |
| 2026-03-19 | SAVA | 2.38 | N/A | N/A | 0 |
| 2026-03-20 | SAVA | 2.38 | N/A | N/A | 0 |
| 2026-03-23 | SAVA | 2.38 | N/A | N/A | 0 |
| 2026-03-24 | SAVA | 2.38 | N/A | N/A | 0 |
| 2026-03-25 | SAVA | 2.38 | N/A | N/A | 0 |
| 2026-03-26 | SAVA | 2.38 | N/A | N/A | 0 |
| 2026-03-27 | SAVA | 2.38 | N/A | N/A | 0 |
| 2026-03-30 | SAVA | 2.38 | N/A | N/A | 0 |
| 2026-03-31 | SAVA | 2.38 | N/A | N/A | 0 |
| 2026-04-01 | SAVA | 2.38 | N/A | N/A | 0 |
| 2026-04-02 | SAVA | 2.38 | N/A | N/A | 0 |
| 2026-04-06 | SAVA | 2.38 | N/A | N/A | 0 |
| 2026-04-07 | SAVA | 2.38 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | SAVA | 2.11 | - | - | -1.93 |
| 2026-03-10 | SAVA | 2.37 | - | - | -1.93 |
| 2026-03-11 | SAVA | 2.37 | - | - | -1.93 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | SAVA | 9.49 | -0.08 | 16.70 |
| 2026-03-10 | SAVA | 9.49 | -0.08 | 16.70 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.3
Avg. EPS Est. Next Quarter
-0.31
Insider Transactions
9.49
Institutional Transactions
-0.08
Beta
-0.82
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
7
Growth Score
17
Sentiment Score
94
Actual DrawDown %
98.4
Max Drawdown 5-Year %
-99.1
Target Price
8
P/E
Forward P/E
PEG
P/S
P/B
1.41
P/Free Cash Flow
EPS
-2.2
Average EPS Est. Cur. Y
-1.93
EPS Next Y. (Est.)
-1.22
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
2.5
Return on Equity vs Sector %
-157.8
Return on Equity vs Industry %
-141.7
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
No data found for SAVA
Cassava Sciences, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 30
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
SAVA
Latest News
—
Caricamento notizie per SAVA…
stock quote shares SAVA – Cassava Sciences, Inc. Stock Price stock today
news today SAVA – Cassava Sciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SAVA – Cassava Sciences, Inc. yahoo finance google finance
stock history SAVA – Cassava Sciences, Inc. invest stock market
stock prices SAVA premarket after hours
ticker SAVA fair value insiders trading